α7 Nicotinic Acetylcholine Receptor as a Potential Therapeutic Target for Schizophrenia

被引：46

作者：

Ishikawa, Masatomo ^{[1
]}

Hashimoto, Kenji ^{[1
]}

机构：

[1] Chiba Univ, Ctr Forens Mental Hlth, Div Clin Neurosci, Chiba 2608670, Japan

来源：

CURRENT PHARMACEUTICAL DESIGN | 2011年 / 17卷 / 02期

关键词：

alpha 7 nicotinic acetylcholine receptors; schizophrenia; smoking; nicotine; P50 auditory evoked potential suppression; agonists; allosteric modulators; VITRO PHARMACOLOGICAL CHARACTERIZATION; POSITIVE ALLOSTERIC MODULATOR; INDUCED COGNITIVE DEFICITS; REPEATED AUDITORY-STIMULI; IN-VIVO CHARACTERIZATION; MIDBRAIN DOPAMINE AREAS; CIGARETTE-SMOKING; P50; SUPPRESSION; PARTIAL AGONIST; DBA/2; MICE;

D O I：

10.2174/138161211795049561

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Accumulating evidence suggests that the alpha 7 subtype of nicotinic acetylcholine receptors (nAChRs) plays a role in the pathophysiology of schizophrenia. Deficits in auditory P50 evoked potential suppression in patients with schizophrenia are associated with decreased density of alpha 7 nAChRs in the brain. Some agonists (e. g., DMXB-A and tropisetron) at alpha 7 nAChRs can improve P50 deficits in patients with schizophrenia. Together, these findings indicate that alpha 7 nAChRs are a potential therapeutic target for schizophrenia. Currently, a number of agonists and allosteric modulators at alpha 7 nAChRs are under development as potential therapeutic drugs. In this article, we review recent topics on alpha 7 nAChR agonists and alpha 7 nAChR allosteric modulators as therapeutic drugs for schizophrenia.

引用

页码：121 / 129

页数：9

共 50 条

[1] α7 Nicotinic Acetylcholine Receptor A Potential Target in Treating Cognitive Decline in Schizophrenia
Jones, Candace
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2018, 38 (03) : 247 - 249
[2] Targeting of α7 Nicotinic Acetylcholine Receptors in the Treatment of Schizophrenia and the Use of Auditory Sensory Gating as a Translational Biomarker
Hashimoto, Kenji
CURRENT PHARMACEUTICAL DESIGN, 2015, 21 (26) : 3797 - 3806
[3] Therapeutic Potential of α7 Nicotinic Acetylcholine Receptors
Bertrand, Daniel
Lee, Chih-Hung L.
Flood, Dorothy
Marger, Fabrice
Donnelly-Roberts, Diana
PHARMACOLOGICAL REVIEWS, 2015, 67 (04) : 1025 - 1073
[4] The Therapeutic Potential of α7 Nicotinic Acetylcholine Receptor (α7 nAChR) Agonists for the Treatment of the Cognitive Deficits Associated with Schizophrenia
Corinne Beinat
Samuel D. Banister
Marco Herrera
Vivian Law
Michael Kassiou
CNS Drugs, 2015, 29 : 529 - 542
[5] The α7 nicotinic acetylcholine receptor: A mediator of pathogenesis and therapeutic target in autism spectrum disorders and Down syndrome
Deutsch, Stephen I.
Burket, Jessica A.
Urbano, Maria R.
Benson, Andrew D.
BIOCHEMICAL PHARMACOLOGY, 2015, 97 (04) : 363 - 377
[6] Discovery and Development of α7 Nicotinic Acetylcholine Receptor Modulators
Mazurov, Anatoly A.
Speake, Jason D.
Yohannes, Daniel
JOURNAL OF MEDICINAL CHEMISTRY, 2011, 54 (23) : 7943 - 7961
[7] Therapeutic Targeting of α7 Nicotinic Acetylcholine Receptors
Papke, Roger L.
Horenstein, Nicole A.
PHARMACOLOGICAL REVIEWS, 2021, 73 (03) : 1118 - 1149
[8] α7 Nicotinic Acetylcholine Receptors: A Therapeutic Target in the Structure Era
Taly, Antoine
Charon, Sebastien
CURRENT DRUG TARGETS, 2012, 13 (05) : 695 - 706
[9] Nicotinic Acetylcholine Receptors are Possible Therapeutic Targets for Schizophrenia
Kohnomi, Shuntaro
Suemaru, Katsuya
Kawasaki, Hiromu
Choshi, Tominari
Hibino, Satoshi
Araki, Hiroaki
YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2009, 129 (02): : 197 - 201
[10] Targeting the nicotinic alpha7 acetylcholine receptor to enhance cognition in disease
Wallace, Tanya L.
Porter, Richard H. P.
BIOCHEMICAL PHARMACOLOGY, 2011, 82 (08) : 891 - 903

← 1 2 3 4 5 →